| Name | Title | Contact Details |
|---|
At Averitas Pharma, we strive to enable people with pain to live and feel more like their true selves. With patients at the forefront of every decision we make, we want more than to envision people not limited by their pain; we work every day with passion and determination to make it a reality. We are currently helping patients by offering the only FDA-approved, non-opioid, topical system for the treatment of neuropathic pain associated with postherpetic neuralgia (post-shingles nerve pain) and for neuropathic pain associated with diabetic peripheral neuropathy of the feet (diabetic nerve pain of the feet). We are proudly building on the 75-year legacy of Grünenthal, a global privately held healthcare company that has been working tirelessly toward a world free of pain by approaching pain as a disease in urgent need of a solution, rather than a mere symptom. We do it because we care. Most of us have either dealt with chronic pain or know someone who has, because it is a burden that far too many people around the world must bear. Our empathy for patients, and our shared sense of mission and purpose, are what inspires us to keep going. And our people are the key to our success. For more information, visit www.averitaspharma.com Community Guidelines: 1. We reserve the right to remove profanity, threatening or harassing content, promotional content and any personal information. 2. Due to FDA fair balance rules, we ask that you not mention any medicines or FDA-approved therapies by name or include links to third-party sites. 3. This site is not a forum for reporting side effects experienced while using an Averitas product. Physicians, other healthcare providers, and patients are encouraged to voluntarily report adverse events involving drugs or medical devices. To make a report you can visit www.fda.gov/medwatch or call 1-800-FDA-1088 For questions about our products call 1-877-900-6479. For more information, ask your healthcare provider or pharmacist.
Medivation Inc., which is now a part of Pfizer, Inc. is focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation`s goal is to transform the treatment of these diseases and offer hope to critically ill patients and their families. With the approval of Xtandi (enzalutamide) capsules in late August 2012 and the product launch immediately following, Medivation is continuing to build and develop a world-class workforce to take the company to the next strategic level. Medivation was founded in 2004 by a group of experienced professionals with a long track record of working together successfully as a team in the pharmaceutical and biotechnology industries. They founded Medivation to leverage that expertise to bridge the medical product development gap between early-stage development and product launch. Medivation currently has 500+ employees located in beautiful downtown San Francisco, CA.
Aviva Labs Inc is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
One Cell Systems is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
FogPharma is dedicated to the creation of a new class of medicines that target human disease drivers currently considered `undruggable`.